JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Tel: +1-832-696-8203
Email: [email protected]
Worldwide Distributors
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Aniracetam is a nootropic drug in senile dementia [1].
Aniracetam (Ro 13-5057) has a piracetam-like chemical structure, 1-p-anisoyl-2-pyrrolidinone. It is selected from a series of related compounds because of its effect in impaired cognitive functions in rodents. In rats, the administration of aniracetam (30mg/kg orally) markedly prevents the CO2 induced impairment of acquisition. It also significantly increases the percentage of rats showing retention of the learned task in both the scopolamine induced transient retrograde amnesia model (50mg/kg orally) and the electroconvulsive shock induced memory disruption model (50mg/kg orally). Besides that, aniracetam can prevent the disruptive effect caused by chloramphenicol or cycloheximide (30mg/kg orally) [1, 2].
References:[1] MIZUKI Y, YAMADA M, KATO I, et al. Effects of aniracetam, a nootropic drug, in senile dementia. A preliminary report.: A Preliminary Report. The Kurume medical journal, 1984, 31(2): 135-143.[2] Cumin R, Bandle E F, Gamzu E, et al. Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents. Psychopharmacology, 1982, 78(2): 104-111.
